All In Biotech

Drug Trial Radar · NCT05039866

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Actual

Start

Aug 16, 2021

Primary completion

Mar 2029

Study completion Mar 2039

Sponsor

Lead sponsor
Sangamo TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 10, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.

Conditions

  • Fabry Disease
  • Fabry Disease, Cardiac Variant

Interventions

  • ST-920Biological

    No study drug is administered in this study. Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate long-term safety of ST-920Time frame: 4 years

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California

  • University of South Florida

    Tampa, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Mt. Sinai Hospital

    New York, New York

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)

    Fairfax, Virginia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • M.A.G.I.C. Clinic Ltd.

    Calgary, Alberta, Canada

  • University Hospital of Würzburg

    Würzburg, Germany

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.